Joseph Pantginis Recent News
This Strata Skin Analyst Is Modeling For More Than 400% Upside In Stock
Analyst Sees Near-Term Inflection Point For Aptose Biosciences, Upgrades Stock
Analyst Makes The Case For Ligand As A 'Core' Holding
Cytokinetics Still A Buy After Phase 2 SMA Data
Aptose Upgraded To Buy At Roth, Price Target Doubled
Roth Resumes Coverage On Fibrocell With Buy Rating, $7 Target
Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It
Flex Pharma Could Still Double From Here, Roth Analyst Says
Roth Capital's New Buy Rating On TetraLogic: 'SMAC'ing Cancer Around'
Prima BioMed Shares Rally Following New Buy Rating, $6 Target From Roth Capital
Roth Capital Expects Aduro Biotech 'To Shine' Next Year After Meeting Management
No Longer A Buy: Roth Capital Downgrades Keryx Biopharma, Slashes Price Target To $6
Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
5 Biotech Stocks Roth Capital Analysts Are Watching
Cytokinetics Surges Amid Roth Capital Raising Its Price Target
Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth